Skip to content

Study · Animal study (in vivo) · mouse · 2023

8 results

Carnosine synthase deficiency aggravates neuroinflammation in multiple sclerosis.

Spaas J, Van der Stede T, de Jager S, van de Waterweg Berends A, Tiane A, Baelde H, Baba SP, Eckhardt M, Wolfs E, Vanmierlo T, Hellings N, Eijnde BO, Derave W

Progress in neurobiology27 Sept 2023Cited by 11 (Europe PMC)

PMID37774767 (opens in a new tab)DOI10.1016/j.pneurobio.2023.102532 (opens in a new tab)PepBankPUB-37774767
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Carns1-KO mice with EAE, exogenous carnosine could partially rescue exaggerated neuroinflammation.

    In plain wordsIn mice with Carns1 deletion and EAE, administered carnosine could partly reduce exaggerated nerve inflammation.

    Peptide
    L-carnosine
    Outcome
    DecreaseNeuroinflammation rescue
    Study

    mousen: not reported in source

    Carns1-KO mice with EAE
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Carns1-KO mice that are devoid of endogenous HCDs display exaggerated neuroinflammation and clinical symptoms during EAE, which could be partially rescued by exogenous carnosine treatment.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Carns1-KO mice with EAE, exogenous carnosine could partially rescue exaggerated clinical symptoms.

    In plain wordsIn mice with Carns1 deletion and EAE, administered carnosine could partly reduce exaggerated clinical symptoms.

    Peptide
    L-carnosine
    Outcome
    DecreaseClinical symptom rescue
    Study

    mousen: not reported in source

    Carns1-KO mice with EAE
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Carns1-KO mice that are devoid of endogenous HCDs display exaggerated neuroinflammation and clinical symptoms during EAE, which could be partially rescued by exogenous carnosine treatment.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

Studies that did not test the peptide alone6

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

  1. 03AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Mechanism

    In mice with EAE, Carns1 knockout and loss of endogenous HCDs exaggerated neuroinflammation.

    In plain wordsIn mice with EAE, Carns1 gene deletion and loss of natural HCDs worsened nerve inflammation.

    Peptide
    L-carnosine
    Outcome
    IncreaseNeuroinflammation after Carns1 knockout
    Study

    mousen: not reported in source

    Carns1-KO mice with EAE
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Carns1-KO mice that are devoid of endogenous HCDs display exaggerated neuroinflammation and clinical symptoms during EAE, which could be partially rescued by exogenous carnosine treatment.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  2. 04AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In mice with EAE, Carns1 knockout and loss of endogenous HCDs exaggerated clinical symptoms.

    In plain wordsIn mice with EAE, Carns1 gene deletion and loss of natural HCDs worsened clinical symptoms.

    Peptide
    L-carnosine
    Outcome
    IncreaseClinical symptoms after Carns1 knockout
    Study

    mousen: not reported in source

    Carns1-KO mice with EAE
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Carns1-KO mice that are devoid of endogenous HCDs display exaggerated neuroinflammation and clinical symptoms during EAE, which could be partially rescued by exogenous carnosine treatment.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  3. 05AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Mechanism

    In Carns1-KO mice, disease worsening was possibly linked to impaired acrolein clearance through a central mechanism.

    In plain wordsIn mice with Carns1 deletion, worse disease was possibly linked to impaired acrolein clearance in the central nervous system.

    Peptide
    L-carnosine
    Outcome
    DecreaseAcrolein clearance
    Study

    mousen: not reported in source

    Carns1-KO mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Worsening of the disease appears to be driven by a central, not peripheral immune-modulatory, mechanism possibly linked to impaired clearance of the reactive carbonyl acrolein in Carns1-KO mice.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  4. 06AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Mechanism

    In the studied models, CARNS1 was not required for normal myelination or remyelination.

    In plain wordsIn mice, CARNS1 was not required for normal myelin formation or repair.

    Peptide
    L-carnosine
    Outcome
    No significant changeMyelination and remyelination
    Study

    mousen: not reported in source

    CARNS1-deficiency models
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In contrast, CARNS1 is not required for normal oligodendrocyte precursor cell differentiation and (re)myelin to occur,
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  5. 07AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In mice, exogenous HCDs did not protect against cuprizone-induced demyelination.

    In plain wordsIn mice, administered HCDs did not protect against cuprizone-induced myelin loss.

    Peptide
    L-carnosine
    Outcome
    No significant changeCuprizone-induced demyelination
    Study

    mousen: not reported in source

    Cuprizone-induced demyelination
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    and neither endogenous nor exogenous HCDs protect against cuprizone-induced demyelination.
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  6. 08LabNot a test of L-carnosine aloneIn vitro (cells)Mechanism

    In oligodendrocyte precursor cells, CARNS1 was not required for normal differentiation.

    In plain wordsIn cells, CARNS1 was not required for normal oligodendrocyte precursor differentiation.

    Peptide
    L-carnosine
    Outcome
    No significant changeOligodendrocyte precursor differentiation
    Study

    mousen: not reported in source

    Oligodendrocyte precursor cells
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In contrast, CARNS1 is not required for normal oligodendrocyte precursor cell differentiation and (re)myelin to occur,
    1 context sentence
    Summary · context
    To uncover if endogenous carnosine is involved in, and protects against, MS-related neuroinflammation, demyelination or remyelination failure, we here studied the HCD-synthesizing enzyme carnosine synthase (CARNS1) in human MS lesions and two preclinical mouse MS models (EAE, cuprizone).

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.